Protease inhibitors from Theobroma cacao impair SARS-CoV-2 replication in vitro

SARS-CoV-2 is a newly emerging virus from the Coronaviridae family that has already infected over 700 million people worldwide and killed over 6 million. This virus uses protease molecules to replicate and infect the host, which makes these molecules targets for therapeutic substances to eliminate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Guimarães Santana, Brenda Conceição, de Almeida Marques, Daisymara Priscila, dos Santos Freitas, Andria, Ferreira, Monaliza Macêdo, de Sousa Lopes, Danielle, Bagno, Flávia Fonseca, Guimarães da Fonseca, Flávio, dos Reis, Jordana Grazziela Alves Coelho, Oliveira Mendes, Tiago Antônio de, Santos, Jane Lima dos, Pirovani, Carlos Priminho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155420/
https://www.ncbi.nlm.nih.gov/pubmed/37153407
http://dx.doi.org/10.1016/j.heliyon.2023.e15860
Descripción
Sumario:SARS-CoV-2 is a newly emerging virus from the Coronaviridae family that has already infected over 700 million people worldwide and killed over 6 million. This virus uses protease molecules to replicate and infect the host, which makes these molecules targets for therapeutic substances to eliminate the virus and treat infected people. Through the protein-protein molecular docking approach, we detected two cystatins from Theobroma cacao, TcCYS3 and TcCYS4, described as papain-like protease inhibitors. These inhibitors decreased SARS-CoV-2 genomic copies without toxicity to Vero cells. There is a need to perform comprehensive studies in relevant animal models and to investigate the action mechanisms of protease inhibitors from Theobroma cacao that control the replication of SARS-CoV-2 in human cells.

Ejemplares similares